Trial · NCT00853307
Adverse events192
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 192
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Refractory) | 3 | 6 | |
| other | Diarrhoea | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Resistant) | 14 | 25 | |
| other | Stomatitis | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Refractory) | 2 | 6 | |
| other | Stomatitis | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Resistant) | 13 | 25 | |
| other | Nausea | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Refractory) | 3 | 6 | |
| other | Nausea | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Resistant) | 11 | 25 | |
| other | Vomiting | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Refractory) | 4 | 6 | |
| other | Vomiting | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Resistant) | 8 | 25 | |
| other | Abdominal pain | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Refractory) | 2 | 6 | |
| other | Abdominal pain | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Resistant) | 8 | 25 | |
| other | Constipation | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Refractory) | 1 | 6 | |
| other | Constipation | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Resistant) | 4 | 25 | |
| other | Ascites | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Refractory) | 1 | 6 | |
| other | Ascites | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Resistant) | 2 | 25 | |
| other | Flatulence | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Refractory) | 1 | 6 | |
| other | Flatulence | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Resistant) | 2 | 25 | |
| other | Abdominal distension | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Refractory) | 0 | 6 | |
| other | Abdominal distension | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Resistant) | 2 | 25 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Refractory) | 0 | 6 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Alisertib 50 mg (Platinum-Resistant) | 2 | 25 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00853307/events